Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.
IPO Year: 2021
Exchange: NASDAQ
Website: tenayatherapeutics.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/10/2024 | Outperform | William Blair | |
11/30/2023 | $7.00 | Outperform | Leerink Partners |
6/15/2022 | $25.00 | Buy | H.C. Wainwright |
8/24/2021 | Outperform | Cowen & Co. | |
8/24/2021 | $31.00 | Overweight | Morgan Stanley |
8/24/2021 | $37.00 | Buy | Chardan Capital |
8/24/2021 | $40.00 | Overweight | Piper Sandler |
4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $18 price target.
William Blair analyst Sami Corwin initiates coverage on Tenaya Therapeutics (NASDAQ:TNYA) with a Outperform rating.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $18 price target.
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.42) by 4.76 percent.
Chardan Capital analyst Geulah Livshits reiterates Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $20 price target.
Canaccord Genuity analyst Whitney Ijem maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and lowers the price target from $19 to $18.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $18 price target.
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.44) by 9.09 percent. This is a 34.43 percent increase over losses of $(0.61) per share from the same period last year.
TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) PKP2 Gene Replacement Therapy Normalized Heart Rhythms, Reversed Disease Progression and Extended Survival in a Severe Mouse Model of DiseaseTenaya Anticipates Dosing First Patient in Phase 1b RIDGE™-1 Clinical Trial of TN-401 in Second Half of 2024
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ:BLND) rose sharply during Friday’s session after the company reported fourth-quarter financial results. Blend Labs posted quarterly loss of 9 cents per share, in-line with market estimates of 9 cents per share. The company’s quarterly sales came in at $36.10 million versus estimates of $36.93 million, according to data from Benzinga Pro. Blend Labs shares jumped 24.3% to $2.92 on Friday. Here are some other big stocks recording gains in today’s session. Cardlytics, Inc. (NASDAQ:CDLX) jumped 57.1% to $12.86 after the company reported better-than-expected fourth-quar
SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)
SC 13D/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)
SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)
SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)
SC 13G - Tenaya Therapeutics, Inc. (0001858848) (Subject)
SC 13D/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)
SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)
SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)
SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)
SC 13D/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)
William Blair initiated coverage of Tenaya Therapeutics with a rating of Outperform
Leerink Partners initiated coverage of Tenaya Therapeutics with a rating of Outperform and set a new price target of $7.00
H.C. Wainwright initiated coverage of Tenaya Therapeutics with a rating of Buy and set a new price target of $25.00
Cowen & Co. initiated coverage of Tenaya Therapeutics with a rating of Outperform
Morgan Stanley initiated coverage of Tenaya Therapeutics with a rating of Overweight and set a new price target of $31.00
Chardan Capital initiated coverage of Tenaya Therapeutics with a rating of Buy and set a new price target of $37.00
Piper Sandler initiated coverage of Tenaya Therapeutics with a rating of Overweight and set a new price target of $40.00
144 - Tenaya Therapeutics, Inc. (0001858848) (Subject)
10-Q - Tenaya Therapeutics, Inc. (0001858848) (Filer)
8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)
8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)
8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)
8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)
10-Q - Tenaya Therapeutics, Inc. (0001858848) (Filer)
8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)
ARS - Tenaya Therapeutics, Inc. (0001858848) (Filer)
DEFA14A - Tenaya Therapeutics, Inc. (0001858848) (Filer)
Oxford Biomedica Appoints Leone Patterson as Non-Executive Director Oxford, UK – 26th April 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led viral vector CDMO, today announces the appointment of Ms Leone Patterson as an Independent Non-Executive Director. Ms Patterson shall join the Board on 1st May 2023. Ms Patterson has more than 20 years of public company biotech experience including in the cell and gene therapy industry and has managed significant growth within international commercial companies working across areas including strategy, finance, operations and governance. She is currently the Chief Financial and Business Officer a
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Amy Burroughs to its Board of Directors. Ms. Burroughs currently serves as President and Chief Executive Officer of Cleave Therapeutics, a clinical-stage company focused on developing novel medicines for oncology and neurodegenerative diseases. "We are pleased to welcome Ms. Burroughs to the Tenaya Board. Her substantial and diverse industry experience in the development and commercia
Company announces development candidate selection of its second gene therapy program, TN-401, targeting the leading genetic cause of arrhythmogenic right ventricular cardiomyopathy (gARVC) IND applications for TN-201 and TN-301 (previously named TYA-11631) expected to be submitted in the second half of 2022 Appoints Jennifer Drimmer, J.D., as General Counsel Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today provided a 2022 business update including the selection of TN-401 as the development candidate for the treatment of Genetic Arrhythmogenic
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced the appointments of Karah Parschauer, J.D., to its Board of Directors and of Joanna Auch as Senior Vice President of People and Culture. "Tenaya is at an important inflection point in our growth and maturity. We are now a public company with more than 100 employees who represent our commitment to internalize critical capabilities, including cGMP manufacturing and clinical development," said Faraz Ali, CEO of Tenaya. "Both Karah and Joanna are strong leaders who bring highly relevant strategic
Received Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TN-201 for MYBPC3-associated Hypertrophic Cardiomyopathy Received UK Clearance to Initiate Clinical Testing of TN-401 for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Established $45 Million Credit Facility with Silicon Valley Bank to Provide Financial Flexibility Ahead of Multiple Potential Milestones SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today repo
Kathy Ivey, Ph.D., Promoted to Senior Vice President, Research and Timothy Hoey, Ph.D., Transitions to Advisory Role Pediatric Cardiologist and Genetic Therapy Expert Barry J. Byrne, M.D., Ph.D., Joins Scientific Advisory Board Board Member Jin-Long Chen, Ph.D., Steps Down SOUTH SAN FRANCISCO, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced changes to its Research leadership team, including new appointments to the company's Scientific Advisory Board (SAB). Kathy Ivey,
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Chief Executive Officer, will participate in the TD Cowen Genetic Medicines & RNA Summit on Friday, June 21, 2024, at 11:20 am ET. The live presentation will be webcast and may be accessed from the Investors section of Tenaya's website. A replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference. About Tenaya TherapeuticsTenaya Ther
Initial Data from Ongoing MyPEAK™-1 Phase 1b of TN-201 Expected in Second Half of 2024 Clinical Sites Activated for RIDGE™-1 Phase 1b Clinical Trial of TN-401 Announced Cost Containment Measures in Alignment with Focus on Generating Data from Clinical-Stage Gene Therapy Programs Raised $47 Million Net Proceeds in First Quarter Financing; Current Cash Runway into Second Half of 2025 SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results fo
SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it will present seven abstracts focused on the company's growing capabilities for discovering and advancing genetic medicines for heart disease at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, being held May 7-11, 2024, in Baltimore, MD. Tenaya has established integrated internal capabilities to broadly enable modality agnostic target validation and the desi
Initial Data from Ongoing MyPeak™-1 Phase 1b of TN-201 for MYBPC3-associated HCM Expected in Second Half of 2024 On Track to Dose First Patient in RIDGE™-1Phase 1b Clinical Trial of TN-401 for PKP2-associated ARVC in Second Half 2024 $47 Million Net Proceeds from Recent Financing Extends Cash Runway into Second Half of 2025 SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results for the fourth quarter and full year ended December 31
TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) PKP2 Gene Replacement Therapy Normalized Heart Rhythms, Reversed Disease Progression and Extended Survival in a Severe Mouse Model of Disease Tenaya Anticipates Dosing First Patient in Phase 1b RIDGE™-1 Clinical Trial of TN-401 in Second Half of 2024 SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced t
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that company management will participate in TD Cowen's 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference 2024. Details of participation are as follows: TD Cowen 44th Annual Health ConferenceFormat: Genetic Medicines PanelDate: Tuesday, March 5Time: 2:10 PM ET – 3:10 PM ET Leerink Partners Global Biopharma Conference 2024Format: Fireside ChatDate: Tuesday, March 12Time:
Highly selective Small Molecule HDAC6 Inhibitor Effectively Reversed Heart Failure and Improved Diastolic Heart Function Alone or in Combination with SGLT2 Inhibitor in Murine Models of Disease SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the publication of preclinical research related to Tenaya's small molecule inhibitors of histone deacetylase 6 (HDAC6), including TN-301, in the February 26, 2024, issue of Nature Communications. The article, t
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten offering of 8,888,890 shares of its common stock at an offering price of $4.50 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 2,222,271 shares of its common stock at a purchase price of $4.499 per each pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 pe
4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
3 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)
4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)